In this video, Motley Fool health-care analyst David Williamson discusses what investors should look for in Eli Lilly's upcoming earnings report, and what the big pharma has in store for 2013.
The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.